Effect of Rosuvastatin Therapy on Troponin I Release Following
Percutaneous Coronary Intervention in Nonemergency Patients
(from the TIP 3 Study)

J 2014

Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

VESELKA, Josef; Petr HÁJEK; Pavol TOMAŠOV; David TESAŘ; Hana BRŮHOVÁ et al.

Základní údaje

Originální název

Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

Autoři

VESELKA, Josef; Petr HÁJEK; Pavol TOMAŠOV; David TESAŘ; Hana BRŮHOVÁ; Martin MATĚJOVIČ; Marian BRANNY; Martin STUDENČAN a David ZEMÁNEK

Vydání

American Journal of Cardiology, Bridgewater, Elsevier Science INC, 2014, 0002-9149

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.276

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00081970

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

PERIPROCEDURAL MYOCARDIAL-INFARCTION; STATIN THERAPY; ATORVASTATIN PRETREATMENT; RANDOMIZED-TRIAL; UNIVERSAL DEFINITION; OUTCOMES; IMPACT; ANGIOPLASTY; REDUCTION; IMPROVES

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 8. 2015 11:18, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end point was the incidence of TnI microleak defined as TnI elevation >1.5 x upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3 x upper limit of normal. The incidence of primary and secondary end point in the rosuvastatin versus control group was 13.6% versus 12% (p = 0.61) and 8.2% versus 7.1% (p = 0.67), respectively. Patients with C-reactive protein >= 2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mu g/L vs 0.056 [0.018 to 0.241] mu g/L; p = 0.04). In conclusion, 1-day rosuvastatin therapy (20 mg twice a day) did not influence post-PCI TnI release in patients with angina. However, these results suggest that, in patients with an advanced inflammatory status, rosuvastatin loading therapy might have a cardioprotective effect.

Citovat

VESELKA, Josef; Petr HÁJEK; Pavol TOMAŠOV; David TESAŘ; Hana BRŮHOVÁ; Martin MATĚJOVIČ; Marian BRANNY; Martin STUDENČAN a David ZEMÁNEK. Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study). American Journal of Cardiology. Bridgewater: Elsevier Science INC, 2014, roč. 113, č. 3, s. 446-451. ISSN 0002-9149. Dostupné z: https://doi.org/10.1016/j.amjcard.2013.10.026.

@article{1165524,
   author = {Veselka, Josef and Hájek, Petr and Tomašov, Pavol and Tesař, David and Brůhová, Hana and Matějovič, Martin and Branny, Marian and Studenčan, Martin and Zemánek, David},
   article_location = {Bridgewater},
   article_number = {3},
   doi = {https://doi.org/10.1016/j.amjcard.2013.10.026},
   keywords = {PERIPROCEDURAL MYOCARDIAL-INFARCTION; STATIN THERAPY; ATORVASTATIN PRETREATMENT; RANDOMIZED-TRIAL; UNIVERSAL DEFINITION; OUTCOMES; IMPACT; ANGIOPLASTY; REDUCTION; IMPROVES},
   language = {eng},
   issn = {0002-9149},
   journal = {American Journal of Cardiology},
   title = {Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)},
   volume = {113},
   year = {2014}
}

TY  - JOUR
ID  - 1165524
AU  - Veselka, Josef - Hájek, Petr - Tomašov, Pavol - Tesař, David - Brůhová, Hana - Matějovič, Martin - Branny, Marian - Studenčan, Martin - Zemánek, David
PY  - 2014
TI  - Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)
JF  - American Journal of Cardiology
VL  - 113
IS  - 3
SP  - 446-451
EP  - 446-451
PB  - Elsevier Science INC
SN  - 00029149
KW  - PERIPROCEDURAL MYOCARDIAL-INFARCTION
KW  - STATIN THERAPY
KW  - ATORVASTATIN PRETREATMENT
KW  - RANDOMIZED-TRIAL
KW  - UNIVERSAL DEFINITION
KW  - OUTCOMES
KW  - IMPACT
KW  - ANGIOPLASTY
KW  - REDUCTION
KW  - IMPROVES
N2  - Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end point was the incidence of TnI microleak defined as TnI elevation >1.5 x upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3 x upper limit of normal. The incidence of primary and secondary end point in the rosuvastatin versus control group was 13.6% versus 12% (p = 0.61) and 8.2% versus 7.1% (p = 0.67), respectively. Patients with C-reactive protein >= 2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mu g/L vs 0.056 [0.018 to 0.241] mu g/L; p = 0.04). In conclusion, 1-day rosuvastatin therapy (20 mg twice a day) did not influence post-PCI TnI release in patients with angina. However, these results suggest that, in patients with an advanced inflammatory status, rosuvastatin loading therapy might have a cardioprotective effect.
ER  -

VESELKA, Josef; Petr HÁJEK; Pavol TOMAŠOV; David TESAŘ; Hana BRŮHOVÁ; Martin MATĚJOVIČ; Marian BRANNY; Martin STUDENČAN a David ZEMÁNEK. Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study). \textit{American Journal of Cardiology}. Bridgewater: Elsevier Science INC, 2014, roč.~113, č.~3, s.~446-451. ISSN~0002-9149. Dostupné z: https://doi.org/10.1016/j.amjcard.2013.10.026.

Přehled o publikaci